Holen Sie sich die Stockscreener-App
2.92
2.99%
-0.09
Vorhandelsmarkt:
2.86
-0.06
-2.05%
Absci Corp Aktie (ABSI) Neueste Nachrichten
Absci, DigitalOcean and other big stocks moving lower in Wednesday's pre-market session - MSN
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley - TipRanks
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $4.2 to $8 - 富途牛牛
Absci (NASDAQ:ABSI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why Blaize Holdings Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
Absci Corp (ABSI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - Moomoo
Absci reports Q4 EPS (20c), consensus (17c) - TipRanks
Absci’s AI-Native Integrated Drug Creation Platform: Advancing Antibody Therapeutics and Biopharma Innovation - Minichart
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates - MSN
Absci Corp’s 2025 Q4 Call: FDA Delays, Oncology Partnership Shifts, and ABS-201 Timeline Contradictions - Bitget
Absci Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Absci’s Q4 2025 earnings miss forecasts, stock dips - Investing.com
Absci Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp. (NASDAQ:ABSI) Reports Mixed Q4 Results Amid Clinical Progress - ChartMill
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Absci (NASDAQ: ABSI) deepens 2025 loss while pushing ABS-201 toward key data - Stock Titan
Absci earnings missed by $0.02, revenue fell short of estimates - Investing.com
Absci (NASDAQ:ABSI) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Absci shares slip nearly 4% on Q4 revenue miss, wider loss than expected - Investing.com
Absci 10-K: Partner revenue $2.8M, Net loss $115.2M, EPS $(0.84) - TradingView
ABSCI ($ABSI) Releases Q4 2025 Earnings - Quiver Quantitative
Absci (NASDAQ: ABSI) highlights ABS-201 trial progress and AI drug platform - Stock Titan
Absci's hair-loss drug is well tolerated in first 3 cohorts - Stock Titan
AbSci Corp options imply 13.4% move in share price post-earnings - TipRanks
Absci forms advisory board for endometriosis drug program - Investing.com
Absci taps Yale, Mayo experts for non-hormonal endometriosis drug - Stock Titan
Earnings Scheduled For March 24, 2026 - Benzinga
Absci Q4 2025 Earnings Call Transcript - MarketBeat
Earnings To Watch: Absci Corp (ABSI) Reports Q4 2025 Result - GuruFocus
ABSI Technical Analysis | Trend, Signals & Chart Patterns | ABSCI CORP (NASDAQ:ABSI) - ChartMill
Form 8K Absci Corp For: 14 January - Investing.com
Absci Corp expected to post a loss of 19 cents a shareEarnings Preview - TradingView
ABSI PE Ratio & Valuation, Is ABSI Overvalued - Intellectia AI
ABSI Forecast, Price Target & Analyst Ratings | ABSCI CORP (NASDAQ:ABSI) - ChartMill
Earnings Preview: Absci Corp to Report Financial Results Post-market on March 24 - 富途牛牛
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Needham Reiterates Buy Rating for Absci (ABSI) with Unchanged Pr - GuruFocus
Absci (NASDAQ:ABSI) Given Buy Rating at Needham & Company LLC - MarketBeat
Heights Capital Management Inc. Makes New Investment in Absci Corporation $ABSI - MarketBeat
Absci Corporation (NASDAQ:ABSI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Absci (ABSI) CLO receives major RSU and stock option grants - Stock Titan
Absci (NASDAQ: ABSI) CFO receives new RSU and stock option awards - Stock Titan
Absci (NASDAQ: ABSI) SVP Bedrick gets RSUs, options and tax withholding - Stock Titan
Absci (NASDAQ: ABSI) CEO granted 2M+ equity units and has shares withheld for taxes - Stock Titan
Absci Corp chief innovation officer Busch buys $229,000 in stock By Investing.com - Investing.com Australia
Absci (NASDAQ:ABSI) Insider Acquires $229,000.00 in Stock - MarketBeat
Absci Corp chief innovation officer Busch buys $229,000 in stock - Investing.com India
Absci (ABSI) innovation chief buys 100K shares at $2.29 each - Stock Titan
Absci Highlights AI Antibody Platform, ABS-201 Hair-Loss Trial Milestones at Leerink Conference - Yahoo Finance
AbSci2026 Funding Rounds & List of Investors - Tracxn
Absci's Andreas Busch to Retire as Chief Innovation Officer, to Serve as Scientific Advisor - TradingView
New Absci medical chief gets option to buy 650,000 company shares - Stock Titan
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Absci (ABSI) director Menelas Pangalos awarded RSUs and stock options - Stock Titan
Absci (NASDAQ: ABSI) CFO reports new RSUs and stock option grant - Stock Titan
Absci (ABSI) CEO Sean McClain receives major equity grants and tax-share withholding - Stock Titan
Absci (ABSI) Chief Innovation Officer has shares withheld for RSU tax obligations - Stock Titan
Absci names Ransi Somaratne as chief medical officer By Investing.com - Investing.com South Africa
Absci (ABSI) CFO has 8,307 shares withheld for RSU tax payment - Stock Titan
Absci Corp (ABSI) director Menelas Pangalos buys 75,095 shares in market - Stock Titan
Tax withholding trims Absci (ABSI) CFO Jonasson’s share count - Stock Titan
Absci (ABSI) CEO has 26,761 shares withheld to cover RSU taxes - Stock Titan
Absci Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer - The Manila Times
Absci names Ransi Somaratne as chief medical officer - Investing.com
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):